Rogerio C. Lilenbaum, MD

Professor of Medicine (Medical Oncology); Chief Medical Officer of Smilow Cancer Hospital

Physician Biography

Dr. Lilenbaum received his medical degree from the Federal University of Rio de Janeiro School of Medicine in Brazil and earned a masters degree in clinical epidemiology and clinical investigation from the Harvard School of Public Health. He completed his hematology/oncology fellowship at Washington University School of Medicine and a clinical and research fellowship at the University of California San Diego.

Clinical Interests

  • Cancer Care Facilities
  • Carcinoma, Non-Small-Cell Lung
  • Geriatrics
  • Lung Neoplasms
  • Mesothelioma
  • Thoracic Neoplasms
  • National Cancer Institute (U.S.)
  • Small Cell Lung Carcinoma

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Medical Oncology: Subset Medical Oncology Faculty

Yale Cancer Center: Thoracic Oncology Program

Yale Medicine

Office of Cooperative Research

Board Certifications

  • Medical Oncology AB of Internal Medicine (1997)

  • Hematology (Internal Medicine) AB of Internal Medicine (1998)

Clinical Trials

Conditions Study Title
Lung Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers
Lung An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
Lung A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy
Lung A Phase III Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in ALK-positive Advanced Lung Cancer Patients
Lung A Phase Ib/II, Open-label, Multicenter Trial With Oral cMET Inhibitor INC280 Alone and in Combination With Erlotinib Versus Platinum With Pemetrexed in Adult Patients With EGFR Mutated, cMET-amplified, Locally Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC) With Acquired Resistance to Prior EGFR Tyrosine Kinase Inhibitor (EGFR TKI)
Lung A Phase 2, Fast Real Time Assessment of Combination Therapies in Immuno-Oncology Study in Subjects With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)
Lung A Phase III, Double-blind, Randomized, Placebo-controlled Multi-centre, Study to Assess the Efficacy and Safety of AZD9291 Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumor Resection With or Without Adjuvant Chemotherapy (ADAURA)
Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Anus, Bladder, Bones and Joints, Brain and Nervous System, Breast - Female, Breast - Male, Cervix Uteri, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Hodgkin's Lymphoma, Kaposi's sarcoma, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Lymphoid Leukemia, Melanoma, skin, Non-Hodgkin's Lymphoma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
Lung Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Lung A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Lung A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PDL1 Antibody) Compared With Cisplatin or Carboplatin + Pemetrexed for PD-L1-Selected Chemotherapy Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer
Lung Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Brain and Nervous System, Lung, Melanoma, skin A Phase II Trial of Pembrolizumab Plus Bevacizumab in Patients With Metastatic Melanoma or Non-small Cell Lung Cancer With Untreated Brain Metastases
Lung A Phase II Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer
Bladder, Lung, Other Digestive Organ, Other Urinary, Stomach, Phase I An Open-Label, Multicenter, Phase I Study of Ramucirumab Plus Pembrolizumab in Patients With Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, or Transitional Cell Carcinoma of the Urothelium
Lung, Melanoma, skin MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
Lung Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer (aboundsqm)
Lung A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer
Lung Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer
Lung, Melanoma, skin Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC

Edit this profile

Contact Info

Rogerio C. Lilenbaum, MD
Patient Care Location
Smilow Cancer Hospital at Yale-New HavenSmilow Cancer Hospital at Yale - New Haven
35 Park Street, Ste North Pavilion 4

New Haven, CT 06511
View on map...
Mailing Address
20 York Street
New Haven, CT 06520-8021